Handok's Amaryl-M gets positive response in Indonesia

Published: 2008-03-13 06:58:00

Updated: 2008-03-13 06:58:00

Handok Pharm's homegrown anti-diabetic agent Amaryl-M, a combined medicine of glimepiride and metformin, received favorable response from Indonesian doctors at a launching symposium held in Jakarta in March 1.

Amaryl is effective as initial drug therapy. In patients where monotherapy with Amar...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK